NCT01345136View on ClinicalTrials.gov

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

February 6, 2024

Study Completion Date

February 6, 2024

Conditions

Neurofibromatosis Type 2Neuroma, Acoustic

Interventions

DRUG

RAD001, everolimus

Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily

Trial Locations (1)

90095-7286

University of California Los Angeles, Los Angeles

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER